NCT07459543Not yet recruitingPhase 4
A Phase 4, Single Arm, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in Participants With Unresectable or Metastatic Melanoma in India.
Bristol-Myers Squibb11 sites in 1 country40 target enrollmentStarted: November 15, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
- Sponsor
- Bristol-Myers Squibb
- Enrollment
- 40
- Locations
- 11
- Primary Endpoint
- Incidence of adverse events (AEs)
Study Overview
Brief Summary
The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in unresectable or metastatic melanoma participants in India.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 12 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1/Lansky Performance Score ≥ 80% for minors (ages 12-17) ONLY.
- •Note: Participants with ECOG PS 2 are allowed if the performance status of 2 is attributable to disease burden (and not to significant comorbidity), and if the investigator and Medical Monitor agree the patient may benefit from treatment.
- •Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) staging system (8th edition).
- •Participants must have measurable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
- •Participants must have completed prior radiotherapy at least 2 weeks prior to study treatment administration.
- •Individuals of Childbearing Potential (IOCBP) must not be pregnant or breastfeeding.
Exclusion Criteria
- •Participants must not have active brain metastases or leptomeningeal metastases.
- •Participants must not have uveal melanoma.
- •Participants must not have an active, known, or suspected autoimmune disease.
- •Note: Participants may enroll with the following conditions:
- •i) type 1 diabetes mellitus; ii) hypothyroidism only requiring hormone replacement; iii) skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment; iv) conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- •- Participants must not have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment.
- •Note: Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
- •Participants must not have a history of myocarditis.
- •Other protocol-defined Inclusion/Exclusion criteria apply.
Arms & Interventions
Administration of Nivolumab + Relatlimab Fixed-Dose Combination (FDC)
Experimental
Intervention: Nivolumab + Relatlimab (Drug)
Outcomes
Primary Outcomes
Incidence of adverse events (AEs)
Time Frame: Up to 30 weeks
Incidence of drug-related AEs
Time Frame: Up to 30 weeks
Incidence of serious adverse events (SAEs)
Time Frame: Up to 30 weeks
Incidence of drug-related SAEs
Time Frame: Up to 30 weeks
Incidence of immune-mediated adverse events (IMAEs)
Time Frame: Up to 30 weeks
AEs leading to discontinuation of treatment
Time Frame: Up to 30 weeks
Number of deaths
Time Frame: Up to 30 weeks
Number of participants with laboratory abnormalities
Time Frame: Up to 30 weeks
Secondary Outcomes
- Objective response rate (ORR) as assessed by investigator, using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1(Up to 30 weeks)
Investigators
Study Sites (11)
Loading locations...
Similar Trials
Withdrawn
Phase 2
Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.Advanced Biliary Tract Cancer(BTC)NCT07369791National Health Research Institutes, Taiwan76
Recruiting
Phase 3
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell CarcinomaAdvanced or Metastatic Renal Cell Carcinoma2023-509711-83-00Bristol Myers Squibb International Corporation265
Completed
Phase 2
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon CancerMSI Negative Colorectal CancerMSI Positive Colorectal Cancer2024-516004-42-01Bristol Myers Squibb International Corporation143
Recruiting
Phase 3
CheckMate 901: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 901Untreated Unresectable or Metastatic Urothelial Cancer2022-501784-40-00Bristol Myers Squibb International Corporation701
Recruiting
Phase 3
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer2023-505773-32-00AbbVie Deutschland GmbH & Co. KG57